Antiviral, antimicrobial and protivokariosnoe tool

 

(57) Abstract:

The invention relates to chemical-pharmaceutical industry, medicine and relates to antiviral, antimicrobial and protivokariosnoe funds. The invention lies in the fact that the tool contains a cytokine in an effective amount and the target additives presented in the form of liquid or soft dosage form further comprises glycerin in an amount of 10 to 90 wt.%. As cytokine declared the tool may contain recombinant interferon in the amount of 103-107ME for 1 g of product and/or recombinant tumor necrosis factor - in the amount of 103-107units per 1 g of product. The claimed tool can optionally contain immunoglobulins in the amount of 1-60 wt.%, including a mixture of IgA, IgG and IgM. The invention provides an increase in the saving activity of cytokine in medicine and improve its therapeutic effects. 3 C.p. f-crystals.

The invention relates to chemical-pharmaceutical industry, medicine and can be used in the manufacture of medicines.

Known medicines containing cytokines, presented in the form of RA, 1, 1997).

The main disadvantage of the known solutions and suspensions containing cytokines, is that they better make extemporal from lyophilised preparations of cytokines due to the rapid inactivation. From the well-known ointments and suppositories containing cytokines, almost no adhesion with secreting mucous membranes. Soft dosage forms containing the cytokines are low output medicinal substance in a hydrophilic environment. In addition, when freeze-drying is the loss of activity of the cytokine.

The closest technical solution is the method of obtaining soft dosage forms on the basis of recombinant2-interferon, namely, that before the manufacture of the drug mixed liquid substance immunoglobulins and liquid substance recombinant2- interferon and filler or liquid substance immunoglobulins and lyophilized recombinant2- interferon (RF patent 2116083, C1, 1997).

The main disadvantage of the prototype is also insufficient protection of cytokines from inactivation and insufficient adhesion with secreting mucous membranes, which reduces the effectiveness of the action is chii large number of detachable.

The technical result of the claimed invention is an increase in the saving activity of the cytokine in medicine and improve its therapeutic effects by reducing the frequency of application of liquid or soft dosage forms containing the cytokine and glycerin, due to the preservative properties of glycerin in respect of cytokines, sufficient adhesion of the alcohol with the surface of the mucous membranes, its pronounced hydrophilicity and absorbed by the surface of the mucous membranes. In addition, since the glycerol formed and utilized in the body in the process of life, it is more acceptable from an environmental point of view the component drugs than synthetic preservatives and hydrophilic ointment bases.

The technical result of the claimed invention is achieved due to the fact that antiviral, antimicrobial and protivokariosnoe tool containing a cytokine in an effective amount and the target additives presented in the form of liquid or soft dosage form further comprises glycerin in an amount of 10-90 wt.%.

As cytokine declared the tool may contain recombinant interferon in the amount of 107units per 1 g of product.

The claimed tool can optionally contain immunoglobulins in the amount of 1-60 wt.%. Including a mixture of IgA, IgG and IgM.

Received the tool increases the effectiveness of the topical treatment of viral, bacterial and candidal lesions of the mucous membranes by reducing the frequency of its use.

Example 1. Mix a solution of recombinant2- interferon in the sediment of immunoglobulins and glycerol to a final concentration of components: 105IU/g recombinant2-interferon, 10 wt.% immunoglobulins in the form of a mixture of IgA, IgG and IgM, 75 wt.% glycerol.

In the obtained liquid dosage form, the activity of interferon was maintained at 1.5 times longer than in aqueous solution without glycerol. The liquid dosage form have sufficient adhesion to the mucous membrane.

Derived drug used for lubrication of the posterior pharyngeal wall in a child 6 years pharyngitis. Procedures were performed once a day for 5 days. As a result of the treatment of clinical symptoms of pharyngitis were completely resolved.

Example 2. Mix a solution of recombinant factor netrestore tumor necrosis-, 90 wt.% glycerol.

In the obtained liquid dosage form, the activity of the cytokine was maintained at 1.2 times longer than in aqueous solution without glycerol. The liquid dosage form have sufficient adhesion to the mucous membrane.

Derived drug used for lubrication of lesions in a patient 23 years in candidal stomatitis. Procedures were performed twice a day for 5 days. As a result of the treatment of the clinical manifestations of oral candidiasis were completely resolved.

Example 3. Mix a solution of recombinant2- interferon and tumor necrosis factor - in the sediment of immunoglobulins and glycerol to a final concentration of components: 103IU/g recombinant 2- interferon, 103units/g of recombinant tumor necrosis factor- , 60 wt.% immunoglobulins in the form of a mixture of IgA, IgG and IgM, 35 wt.% glycerol.

In the obtained liquid dosage form, the activity of cytokines remained at 1.2 times longer than in aqueous solution without glycerol. The liquid dosage form have sufficient adhesion to the mucous membrane.

Received the drug is the lack of drops. Procedures were performed once a day for 5 days. As a result of the rehabilitation of the patient within 6 months to 3 times less than in the previous year, was observed episodes of acute respiratory viral infections.

Example 4. Mix a solution of recombinant 2- interferon in the sediment of immunoglobulins, glycerin and ointment base to final concentrations of components: 105IU/g recombinant2-interferon, 1 wt.% immunoglobulins in the form of a mixture of IgA, IgG and IgM, 19 wt.% glycerol, 65 wt.% ointment bases.

In the resulting soft dosage form active cytokines remained at 1.4 times longer than similar soft dosage form without the glycerin. Received soft dosage form have sufficient adhesion to the mucous membrane.

Derived drug used for lubrication of the tonsils at the child of 8 years with catarrhal angina. Procedures were performed once a day for 5 days. As a result of the treatment of clinical symptoms of catarrhal angina resolved.

Example 5. Mix a solution of recombinant 2- interferon and recombinant tumor necrosis factor - in the sediment immunodeficiency is bimantoro2-interferon, 104units/g of recombinant tumor necrosis factor- , 20 wt.% immunoglobulins in the form of a mixture of IgA, IgG and IgM, 10 wt.% glycerol, 65 wt.% filler, and produce suppositories.

In the resulting soft dosage form active cytokines remained at 1.4 times longer than similar soft dosage form without the glycerin. Received soft dosage form have sufficient adhesion to the mucous membrane.

Received the drug was administered intrawaginalno when erosion of the cervix, the patient 25 years. Procedures were performed once a day for 7 days. As a result of treatment of cervical erosion was salpetersaure.

1. Antiviral, antimicrobial and protivokariosnoe tool containing a cytokine in an effective amount and the target additives presented in the form of liquid or soft dosage form, characterized in that it further comprises glycerin in an amount of 10 to 90 wt.%.

2. Antiviral, antimicrobial and protivokariosnoe tool under item 1, characterized in that as it contains cytokine recombinant interferon in the amount of 102- 107IU per 1 g of product 3. Antiviral, antimicrobial and protivokariosnoe tool under item 1 or 2, characterized in that it additionally contains immunoglobulins in the amount of 1 to 60 wt.%.

4. Antiviral, antimicrobial and protivokariosnoe tool on p. 3, characterized in that the antibodies it contains a mixture of IgA, IgG and IgM.

 

Same patents:

The invention relates to medicine, namely to clinical immunology, and the development and use of a new immunoglobulin drug against hepatitis B
The invention relates to the production of specific immunoglobulins for intravenous
The invention relates to the production of specific immunoglobulins for intravenous

The invention relates to biotechnology

The invention relates to humanized antibodies and their binding proteins which are capable of contacting the T cell with certain variable beta chain

The invention relates to medicine, in particular to Oncology and immunology, and for the treatment of b-cell lymphoma

The invention relates to medicine, in particular to immunology, and can be used for neutralization of TNFy patient in need of such neutralization
The invention relates to medicine, specifically to medicinal drug on the basis of immunoglobulins

The invention relates to biotechnology and immunology, and can be used to obtain stable forms of immunobiological preparations that retain their specific characteristics in a long time

The invention relates to medicine, namely to the field of preparative biochemistry, and for onlinebingo, method of its production and pharmaceutical compositions containing onlineby
The invention relates to medicine, gynecology

The invention relates to pharmaceutically acceptable compositions are in the form of a lyophilisate containing the protein as an active start

Antitumor agent // 2136278
The invention relates to the field of medicine and relates to antitumor therapy

The invention relates to biotechnology, in particular to the protein containing two subunits R40 interleukin-12, which are associated with one another preferably by means of at least one disulfide bond with mol
The invention relates to medicine, namely to obstetrics and gynecology
The invention relates to medicine, namely to obstetrics and gynecology, and for the treatment of cervical pathology of viral etiology

The invention relates to medicine, physical therapy
The invention relates to medicine, namely to bacteriology, and relates to a method of determining the sensitivity of the microbe to the antibiotic

FIELD: medicine, hepatology.

SUBSTANCE: invention relates to a method for treatment of chronic hepatitis. Method involves applying granocyte that is administrated every day intravenously in the dose 1-10 mcg/kg of patient weight per 24 h for 7 days, not above, in combination with conventional complex used in treatment of this disease. Method provides normalization of activity of blood enzymes that indicates the liver function recovery and improvement of the liver structure indices.

EFFECT: improved method for treatment.

2 ex

Up!